XML 61 R32.htm IDEA: XBRL DOCUMENT v3.24.1
Group Information (Tables)
 12 Months Ended
Dec. 31, 2023
Interests In Other Entities [Abstract]  
Summary of Information about Subsidiaries
The consolidated financial statements include the following subsidiaries:
% equity interest
NameCountry of incorporationRegistered officeDecember 31, 2023December 31, 2022
BioNTech BioNTainer Holding GmbHGermanyMainz 100 %100 %
BioNTech Cell & Gene Therapies GmbHGermanyMainz 100 %100 %
BioNTech Delivery Technologies GmbHGermanyHalle100 %100 %
BioNTech Diagnostics GmbHGermanyMainz 100 %100 %
BioNTech Europe GmbHGermanyMainz 100 %100 %
BioNTech Idar-Oberstein Services GmbHGermanyIdar-Oberstein 100 %100 %
BioNTech Individualized mRNA Manufacturing GmbHGermanyMainz 100 %100 %
BioNTech Innovation and Services Marburg GmbHGermanyMarburg100 %100 %
BioNTech Innovation GmbHGermanyMainz 100 %100 %
BioNTech Innovative Manufacturing Services GmbHGermanyIdar-Oberstein 100 %100 %
BioNTech Manufacturing GmbHGermanyMainz 100 %100 %
BioNTech Manufacturing Marburg GmbHGermanyMarburg100 %100 %
BioNTech Real Estate Holding GmbHGermanyHolzkirchen100 %100 %
BioNTech Real Estate Verwaltungs GmbHGermanyHolzkirchen100 %100 %
InstaDeep DE GmbHGermanyBerlin 100 %
n/a(2)
JPT Peptide Technologies GmbHGermanyBerlin 100 %100 %
NT Security and Services GmbHGermanyMainz 100 %100 %
reSano GmbHGermanyMainz 100 %100 %
BioNTech Australia Pty Ltd.AustraliaMelbourne100 %100 %
BioNTech R&D (Austria) GmbHAustriaVienna100 %100 %
BioNTech (Shanghai) Pharmaceuticals Co. Ltd.ChinaShanghai100 %100 %
InstaDeep France SASFranceParis100 %
n/a(2)
Biopharma BioNTech Israel Ltd.IsraelTel Aviv100 %
n/a(1)
New Technologies ReLuxembourgLuxembourg100 %
n/a(1)
InstaDeep Nigeria LimitedNigeriaLagos100 %
n/a(2)
BioNTech Rwanda Ltd.RwandaKigali100 %100 %
BioNTech Sénégal SuarlSenegalDakar100 %
n/a(1)
BioNTech Pharmaceuticals Asia Pacific Pte. Ltd.SingaporeSingapore100 %100 %
BioNTech Pharmaceuticals Spain S.LSpainBarcelona100 %
n/a(1)
BioNTech Switzerland GmbHSwitzerlandBasel100 %
n/a(1)
BioNTech Taiwan Co. Ltd.TaiwanTaipei100 %
n/a(1)
InstaDeep Tunisia SARLTunisiaTunis100 %
n/a(2)
BioNTech Turkey Tıbbi Ürünler Ve Klinik Araştirma Ticaret Anonim ŞirketiTürkiyeIstanbul100 %100 %
BioNTech UK Ltd.United KingdomLondon100 %100 %
InstaDeep Ltd.United KingdomLondon100 %
5.3%(2)
BioNTech Research and Development, Inc.United States Cambridge100 %100 %
BioNTech USA Holding, LLCUnited States Cambridge100 %100 %
BioNTech US Inc.United States Cambridge100 %100 %
BioNTech Delivery Technologies (US), LLCUnited States Cambridge100 %
n/a(2)
InstaDeep LLCUnited States Dover100 %
n/a(2)
JPT Peptide Technologies Inc.United States Cambridge100 %100 %
(1)    Included during the year ended December 31, 2023.
(2)    Fully acquired during the year ended December 31, 2023.
Summary of Information about Parent Company
ATHOS KG, Holzkirchen, Germany, is the sole shareholder of AT Impf GmbH, Munich, Germany, and beneficial owner of the following percentage of ordinary shares in BioNTech at the dates as indicated. ATHOS KG via AT Impf GmbH has de facto control over BioNTech based on its substantial shareholding, which practically enables it to exercise the majority of voting rights to pass resolutions at our Annual General Meeting, or AGM.
Ownership of ordinary shares in BioNTech (in %)
NameCountry of incorporationRegistered officeDecember 31, 2023December 31, 2022
AT Impf GmbHGermanyMunich43.77 %43.42 %
Summary of Information about Entity with Significant Influence Over Group
Medine GmbH, Mainz, Germany, owned the following percentage of ordinary shares in BioNTech at the following dates as indicated:
Ownership of ordinary shares in BioNTech (in %)
NameCountry of incorporationRegistered officeDecember 31, 2023December 31, 2022
Medine GmbHGermanyMainz17.01 %17.38 %